Medicine guide

There is no universal “best” weight-loss injection.

Compare three commonly discussed active ingredients by authorised purpose, schedule, clinical context and continuity — then explore the full injection library.

The essential distinction

Similar conversations do not mean identical medicines.

Semaglutide and liraglutide are GLP-1 receptor agonists. Tirzepatide acts on GIP and GLP-1 receptors. They differ in evidence, dosing schedules, product information, restrictions and how a clinician may monitor treatment.

Brand names are especially easy to confuse: the same active ingredient may appear in products authorised for different conditions. Ask the prescriber to write down the active ingredient, product name, indication and plan.

01Usually weekly for injectable products

Semaglutide

GLP-1 receptor agonist

Different semaglutide brands and formulations can have different authorised uses. A diabetes brand is not automatically interchangeable with a weight-management product.

Ask your prescriber

What is the exact product, authorised purpose and written titration plan?

02Usually weekly

Tirzepatide

GIP / GLP-1 receptor agonist

Tirzepatide acts on two hormone-receptor pathways. Eligibility and product indications vary by country and should be checked against current local information.

Ask your prescriber

Why is this treatment appropriate for me, and who reviews my response?

03Usually daily

Liraglutide

GLP-1 receptor agonist

Liraglutide has been used for weight management for longer than newer weekly options. Its frequency and reassessment points differ.

Ask your prescriber

What is the escalation schedule and when will benefit be reassessed?

Beyond the main three

See every injection by regulatory status.

The portal also covers setmelanotide, diabetes-only GLP-1 medicines, investigational compounds such as retatrutide and products not approved for weight loss.

Open all 13 guides

Before starting

What your clinician needs to know.

  • Your full medicine and supplement list
  • Diabetes treatment and history of low blood sugar
  • Digestive, gallbladder, pancreatic and kidney history
  • Pregnancy, breastfeeding or pregnancy plans
  • Planned surgery, sedation or anaesthesia
  • Previous weight-management treatment and response

This is not a complete eligibility screen. The official product information and your clinical history govern the decision.

A safer product conversation

Six details to get in writing.

A verbal promise of “the same injection” is not enough to identify a medicine or a safe treatment plan.

  1. 1Active ingredient and exact brand
  2. 2Authorised use for the product supplied
  3. 3Starting plan and review schedule
  4. 4Named prescriber and dispensing pharmacy
  5. 5Storage rules before and during travel
  6. 6What happens if the intended product is unavailable

Do not substitute casually

Never switch products or copy a dose from social media.

Different pens, concentrations and schedules can create dosing errors. The FDA has reported serious adverse events associated with errors involving some unapproved compounded injectable products. Use only the specific product and instructions provided by a qualified prescriber and licensed pharmacy.

Primary sources

Check the source, not just the summary.

Next guide

Make safety the first filter.

Go to safety